Connect with us


Omeros Sells Omidria to Rayner Surgical in $1B Deal

The product is used during cataract surgery and intraocular lens replacement.




SEATTLE — Omeros Corp. has completed the sale of Omidria, a drug for use during eye surgery, to Rayner Surgical Group Inc.

Seattle-based Omeros (Nasdaq: OMER) received approximately $126 million in cash at closing. In addition, Omeros retains the full amount of accounts receivable outstanding as of closing. It’s also eligible to receive $200 million in a commercial milestone payment.

Together with royalties to be paid by Rayner to Omeros on net sales of Omidria, the transaction is valued in excess of $1 billion.

Omidria (phenylephrine and ketorolac intraocular solution 1.0%/0.3%) is an FDA-approved product marketed in the U.S. for use during cataract surgery or intraocular lens replacement. It maintains pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. It is the only NSAID-containing product FDA-approved for intraocular use.

Omidria will become a key product in Rayner’s ophthalmology franchise, which includes intraocular lenses, ophthalmic viscoelastic devices and dry eye treatments, according to a press release. As part of the agreement, Rayner acquired the Omidria commercial organization, including its sales force. United Kingdom-based Rayner plans to expand the sales force both inside and outside the U.S.



Explore New Crizal® Sapphire™ HR lenses on Leonardo

Did you know there’s an online course on the new Crizal Sapphire HR lenses available now on Leonardo? With best-in-class learning content, including a wide range of ABO certified CE courses, Leonardo can take your practice’s optical knowledge to the next level. Visit today to learn about new Crizal Sapphire HR and take advantage of the 3-month free trial of this innovative online learning platform brought to you by EssilorLuxottica.

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular